Association of HRD Score With Efficacy of Neoadjuvant Short-Course Radiotherapy Plus Sequential Chemoimmunotherapy in pMMR Locally Advanced Rectal Cancer.
Xin Ran, He Xiao, Peng Zhou et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II clinical trial examined the relationship between homologous recombination deficiency (HRD) score and treatment response in 32 patients with mismatch repair-proficient locally advanced rectal cancer receiving neoadjuvant short-course radiotherapy and sequential chemoimmunotherapy. The study found a significant difference in HRD score distribution between patients achieving pathological complete response (pCR) and those who did not (p = 0.017).
Key findings
- The overall pCR rate was 40.62% (13/32) among the cohort.
- Patients with high HRD scores had the highest CD8+ T-cell abundance.
- 61.54% of pCR patients had low HRD scores compared to 31.58% of non-pCR patients.
Why it matters
Understanding the association between HRD scores and treatment response can help clinicians identify patients who may benefit more from specific neoadjuvant therapies, potentially improving outcomes in locally advanced rectal cancer.